2023
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
Ji S, Liu H, Pachella L, Stephenson R, Groisberg R, Weiss S. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Frontiers In Transplantation 2023, 2: 1284740. PMID: 38993910, PMCID: PMC11235332, DOI: 10.3389/frtra.2023.1284740.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCutaneous squamous cell carcinomaObjective response rateMerkel cell carcinomaSolid organ transplant recipientsOrgan transplant recipientsSOT recipientsGraft rejectionCutaneous malignanciesCheckpoint inhibitorsTransplant recipientsCell carcinomaRetrospective analysisFirst-line immune checkpoint inhibitorsPrior systemic therapyAdvanced skin cancerSquamous cell carcinomaAdvanced cutaneous malignanciesImmunosuppressive therapyAllograft rejectionGraft failureSystemic therapyAdvanced melanomaCare therapyImmunosuppressive agentsCase report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases
Rusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. Frontiers In Oncology 2023, 13: 1217816. PMID: 37476373, PMCID: PMC10354444, DOI: 10.3389/fonc.2023.1217816.Peer-Reviewed Case Reports and Technical NotesMerkel cell carcinomaDuration of surveillanceLate recurrenceCell carcinomaMetastatic Merkel cell carcinomaPrimary Merkel cell carcinomaMetastases 15 monthsSuch late recurrencesPredictors of recurrenceNodal recurrenceDefinitive therapyFirst recurrenceDisease resectionNodal metastasisPhysical examinationRare tumorPrimary diagnosisPrimary tumorRisk factorsHigh riskNational guidelinesRecurrenceOptimal durationPatientsCarcinoma
2020
Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical Notes
2017
Microvessel density as a prognostic marker in high-risk renal cell carcinoma.
Weiss S, Puligandla M, Jilaveanu L, Haas N, Wang X, Zito C, Boeke M, Neumeister V, Manola J, DiPaola R, Kluger H. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal Of Clinical Oncology 2017, 35: 4565-4565. DOI: 10.1200/jco.2017.35.15_suppl.4565.Peer-Reviewed Original ResearchHigher microvessel densityRenal cell carcinomaDisease-free survivalHigh-risk renal cell carcinomaOverall survivalMicrovessel densityTreatment armsEntire cohortCell carcinomaNephrectomy specimensGrade I/IIVascular endothelial growth factor (VEGF) pathwayStratified log-rank testEndothelial growth factor pathwayClear cell renal cell carcinomaImproved overall survivalCell renal cell carcinomaClear cell histologyShorter overall survivalLog-rank testTumor microvessel densityAbsence of necrosisGrowth factor pathwaysAdjuvant sunitinibImproved OS
2015
Role of the Medical Oncologist in the Management of Skin Cancer
Weiss S, Wilson M, Pavlick A. Role of the Medical Oncologist in the Management of Skin Cancer. Current Dermatology Reports 2015, 4: 205-212. DOI: 10.1007/s13671-015-0119-0.Peer-Reviewed Original ResearchMetastatic skin cancerMedical oncologistsCell carcinomaSkin cancerSquamous cell carcinomaMerkel cell carcinomaBasal cell carcinomaSystemic therapyLocal therapyMedical oncologySurgical oncologyField of dermatologyCancerCarcinomaOncologistsRadiation oncologyMedical specialistsOncologyTherapyMulti-disciplinary approachPertinent evidenceSurgeryMelanomaManagementRecurrent